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ABSTRACT 
 
Hepatitis C virus (HCV) translation is mediated by a highly conserved internal 
ribosome entry site (IRES), mainly located at the 5‟untranslatable region (5‟UTR) of the 
viral genome. Viral protein synthesis clearly differs from that used by most cellular 
mRNAs, rendering the IRES an attractive target for novel antiviral compounds. The 
engineering of RNA compounds is an effective strategy for targeting conserved 
functional regions in viral RNA genomes. The present work analyses the anti-HCV 
potential of HH363-24, an in vitro selected molecule composed of a catalytic RNA 
cleaving domain with an extension at the 3‟ end that acts as aptamer for the viral 
5‟UTR. The engineered HH363-24 efficiently cleaved the HCV genome and bound to 
the essential IIId domain of the IRES region. This action interfered with the proper 
assembly of the translationally active ribosomal particles 48S and 80S, likely leading to 
the effective inhibition of IRES function in a hepatic cell line. HH363-24 also 
efficiently reduced HCV RNA levels up to 70% in a subgenomic replicon system. 
These findings provide new insights into the development of potential therapeutic 
strategies based on RNA molecules targeting genomic RNA structural domains and 
highlight the feasibility of generating novel engineered RNAs as potent antiviral agents. 
 
Keywords: Antiviral tools; Anti-HCV compounds; Aptamer; HCV targeting; RNA-
based inhibitors. 
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1. INTRODUCTION 
 
Hepatitis C virus (HCV) is the sole member of Hepacivirus, a genus belonging to the 
family Flaviviridae. It is responsible for chronic liver disease that frequently leads to 
cirrhosis and occasionally hepatocellular carcinoma (Hoofnagle, 1997). Current 
therapeutic strategies based on the use of alpha interferon (α-IFN) and ribavirin only 
achieve the complete clearance of viral particles in a limited number of patients. 
Moreover, resistance to anti-HCV compounds can develop quickly and expand among 
viral pools. Novel antiviral options are therefore required.  
The direct targeting of functional genomic domains is a promising option for the control 
of infection (Romero-López et al., 2006). This might be undertaken alone or in 
combination with generic antiviral drugs. The HCV genome is a 9600 nt-long, positive, 
single-stranded RNA molecule that exists as a ribonucleoprotein particle covered by a 
lipid envelope (Ishida et al., 2001). It encodes a unique open reading frame (ORF) 
flanked by two highly conserved untranslatable regions (5‟ and 3‟UTRs; (Choo et al., 
1989; Kato et al., 1990; Takamizawa et al., 1991); these are extensively folded domains 
with essential roles in viral protein synthesis and replication (Friebe and Bartenschlager, 
2002; Friebe et al., 2001; Tsukiyama-Kohara et al., 1992; Wang et al., 1993). The 
initiation of HCV translation, a crucial step in early infection, is governed by an internal 
ribosome entry site element (IRES) mostly located at the 5‟UTR but spanning 40 nt of 
the coding sequence (Figure 1A; (Reynolds et al., 1995; Tsukiyama-Kohara et al, 1992; 
Wang et al, 1993). Operating in a cap-independent manner it bypasses most of the 
control pathways involved in the translational regulation of cellular mRNAs. The 
initiation of viral protein synthesis is mainly influenced by the three-dimensional 
folding of the IRES element (Figure 1A; (Collier et al., 2002; Kieft et al., 2002; 
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Lukavsky et al., 2000; Odreman-Macchioli et al., 2000) and involves the direct binding 
of the ribosomal subunit 40S to domain IIId (Figure 1A; (Babaylova et al., 2009; Ji et 
al., 2004; Kolupaeva et al., 2000; Lytle et al., 2002; Otto and Puglisi, 2004). This 
functional genomic element is a highly conserved domain in the HCV IRES consisting 
of a short stem with an internal E loop and an apical loop folded into a U-turn motif 
(Figure 1A;(Jubin et al., 2000; Klinck et al., 2000; Lukavsky et al, 2000; Smith et al., 
1995). Domain IIId has specific structural features that determine its plasticity and 
predisposition to interact with both proteins and nucleic acids to achieve its most stable 
conformation (Babaylova et al, 2009; Kolupaeva et al, 2000; Lafuente et al., 2002; 
Lukavsky et al, 2000; Romero-López and Berzal-Herranz, 2009; Shimoike et al., 1999). 
Along with its crucial role in viral translation, the 5‟UTR also participates in HCV 
replication (Friebe et al, 2001). All these items make the IRES, and particularly domain 
IIId, outstanding candidates for HCV targeting. 
The use of nucleic acids - particularly RNA molecules - as anti-HCV agents has been 
extensively reported (Romero-López et al, 2006), and references therein). The use of 
aptamers as such is an attractive option since their mechanism of action is based on the 
direct recognition of primary, secondary and even tertiary structure. The functioning of 
antisense and siRNAs, in contrast, relies on sequence complementarity. The structural 
recognition of conserved genomic elements is important for engineering new 
therapeutic tools that reduce the appearance of resistant viral mutants, a major goal in 
the search for long-term treatments. The combination of several inhibitors with different 
specificities might also help hold back the generation of escape variants (Jarczak et al., 
2005; Macejak et al., 2001). 
A hammerhead ribozyme that targets positions 357-369 of the HCV genome and 
cleaves it at 3‟ of the nucleotide C363 (HH363; (Lieber et al., 1996) was extended at its 
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3‟ end with a random sequence. A two-step in vitro selection method (Romero-López et 
al., 2005) was then used to isolate RNA compounds with double activity: a common 
catalytic core fused to different aptamers for the viral 5‟UTR. Such engineered 
hammerhead ribozymes may interfere with HCV IRES function (Romero-López et al, 
2005). Tests on the antiviral role of one of these molecules, HH363-24 (Figure 1B), 
showed it to efficiently cleave the HCV genome as well as bind and block the function 
of the targeted IIId domain of the IRES.  In a human liver-derived cell line it prevented 
both translation and replication steps of the viral cycle.  
 
2. MATERIALS AND METHODS 
 
2.1. Cell lines and culture conditions 
The human hepatoma cell line Huh-7 was maintained in Dulbecco‟s modified Eagle‟s 
medium (DMEM), supplemented with 10% (v/v) heat-inactivated foetal bovine serum 
(FBS; Invitrogen, Carlsbad, CA, USA) and 1 mM sodium pyruvate (Sigma, St. Louis, 
MO, USA), at 37ºC in a 5% CO2 atmosphere. Cells harbouring the bicistronic, 
subgenomic HCV replicon Huh-7 NS3-3‟ (Larrea et al., 2006; Romero-López et al., 
2009) were grown in DMEM supplemented with 20% heat-inactivated FBS, 1 mM 
sodium pyruvate and 0.5 mg/ml G-418. 
 
2.2. DNA templates and RNA synthesis 
The RNA molecules used in in vitro analysis were all produced and purified as 
previously described (Barroso-delJesus et al., 1999). For ex vivo inhibition assays, RNA 
synthesis was performed using the RiboMAX
TM
-T7 large-scale RNA production system 
(Promega, Madison, WI, USA; (Romero-López et al, 2009; Romero-López et al., 2007).  
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DNA templates for the RNAs 5‟HCV-356, 5‟HCV-691, 5‟HCV-691gg, RNA80, IRES-
FLuc and cap-Rluc were obtained as previously described (Romero-López et al, 2005; 
Romero-López et al, 2009; Romero-López et al, 2007). The molecule RNA334 used in 
RNA probing assays was generated by in vitro transcription from the pBSSK plasmid 
digested with the restriction enzyme PvuII. 
The dsDNAs encoding HH363-24, HH363m-24, HH363-24m and HH363m-24m were 
generated by annealing and extension of specific oligonucleotides, as described in 
(Barroso-delJesus et al., 2005): 5‟HH363is (5‟-
TATGAATTCTAATACGACTCACTATAGGGTTCTTTCTGATGAGTCCGTgaggac
gaaaggttt-3‟) and asHH363-24 (5‟- 
GCTGAAAGCTTGGATCCGCTCAGGTGTTGGGGACCTGCTCGGACGGCaaaccttt
cgtcctc-3‟) were used to yield the construct HH363-24; 5‟T7pHH363m (5‟-
TAATACGACTCACTATAGGGTTCTTTCTGATAAGTCCGTgaggacgaaaggttt-3‟) 
and asHH363-24 were used to generate HH363m-24; 5‟HH363is was used with 
asHH363-24m (5‟-
GCTGAAAGCTTGGATCCGCTCAGGTGTACCCGACCTGCTCGGACGGCaaaccttt
cgtcctc-3‟) to generate HH363-24m; 5‟T7pHH363m was used with asHH363-24m to 
generate HH363m-24m. The T7 promoter sequence is underlined; lower case letters 
indicate the complementary residues. 
 
2.3. Binding reactions 
The evaluation of the dissociation constant (Kd) for each inhibitor RNA was essentially 
performed as previously reported (Romero-López et al, 2005; Romero-López et al, 
2009). The resulting inhibitory RNA-target complexes were resolved, analysed and 
quantified as previously described (Romero-López et al, 2005; Romero-López and 
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Berzal-Herranz, 2009; Romero-López et al, 2009). The Kd values were calculated from 
the equation y = (Bmax·X)/(Kd+X) (Puerta-Fernández et al., 2005), where y is the 
percentage of complexed inhibitor RNA, Bmax corresponds to the amplitude of the 
reaction, and X represents the concentration of the substrate RNA 5‟HCV-691gg. 
 
2.4. Cleavage assays 
The catalytic activity of HH363-24 was determined as previously described (Barroso-
delJesus et al, 1999; Romero-López et al, 2009). Cleavage products were resolved and 
identified in 4% denaturing polyacrylamide gels. Data were fitted to a non-linear 
equation, y = y0 + a·(1-e
-k
obs
t
), where y represents the percentage of cleavage, a is the 
final extent of the cleavage reaction, t corresponds to time, and kobs is the rate constant.  
 
2.5. RNA-RNA interaction probing assays 
RNA probing assays of the HH363-24:5‟UTR complex were essentially performed as 
described previously (Romero-López et al, 2009; Romero-López et al, 2007). Briefly, 
50 fmol of the 
32P 5‟-end labelled RNA molecule (~200 cps) under study were 
incubated with a molar excess (10 pmol) of the non-labelled partner (5‟HCV-356 for 
HH363-24 probing or the chimeric inhibitor for 5‟UTR probing). Control reactions 
were performed in the presence of an equal amount of a non-related RNA (RNA334 or 
tRNA respectively). Complexes were constructed as described above. Degradation 
reactions were initiated by the addition of RNase T1 (0.1 U), RNase A (0.2 ng) or Pb
2+
 
acetate (30 mM). They were allowed to proceed at 37ºC for 5, 2 and 5 min respectively.  
Two micrograms of tRNA were added to avoid massive degradation. Cleavage was 
halted by the addition of 50 mM EDTA, followed by phenol extraction and ethanol 
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precipitation. The resulting products were analysed in high-resolution denaturing 
polyacrylamide gels (6%). These were dried, scanned and analysed as above.   
 
2.6. Ribosome-IRES complex assembly  
The identification of 48S and 80S ribosomal particles was essentially performed as 
previously described (Romero-López et al, 2009; Romero-López et al, 2007). Briefly, 
40 nM of 
32
P-internally labelled IRES-FLuc RNA was incubated with 5 µM of each 
inhibitor RNA and 7 µl of the translation mix containing 60% cell extract (Flexi
®
 rabbit 
reticulocyte lysate system; Promega, Madison, WI, USA). Ribosomal assembly was 
achieved by incubation at 30ºC for 20 min. Translational complexes were loaded onto a 
linear continuous sucrose gradient (10-30%) and then resolved by ultracentrifugation at 
30,000 rpm for 4 h. Fractions of 0.5 ml were collected from the top of the gradient and 
their radioactivity measured in a QuickCount QC-4000/XER Benchtop Radioisotope 
Counter (Bioscan, Inc., Washington DC, USA). 
 
2.7. RNA transfection 
Cell lines Huh-7 and Huh-7 NS3-3’ were transfected basically as previously reported 
(Romero-López and Berzal-Herranz, 2012; Romero-López et al, 2009; Romero-López 
et al, 2007). Briefly, 24 h before transfection, 90,000 cells were seeded onto a 24-well 
plate and allowed to reach 80-90% confluency. For the analysis of IRES-dependent 
translation inhibition, a mixture containing 1.5 µg of the RNA reporter constructs IRES-
FLuc and cap-RLuc was supplemented with 5 µg (~180 pmol) of each inhibitor 
molecule or the non-related RNA80. This was employed for the transfection of Huh-7 
cells using the TransFectin
TM
 reagent (Bio-Rad, Hercules, CA, USA) following the 
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manufacturer‟s instructions. Luciferase activity was detected 17 h after transfection 
using the Dual-Luciferase
TM
 reporter assay system (Promega).  
To examine the interference of the chimeric RNAs on HCV replication, cells stably 
harbouring the bicistronic subgenomic HCV replicon construct Huh-7 NS3-3‟ were 
cultured as above and transfected with 5 µg of inhibitor or control RNA molecules, 
using TransFectin. They were harvested 18 h later for subsequent analysis. 
 
2.8. Relative quantification of HCV replicons 
Intracellular HCV replicon positive-strand RNA levels were measured as previously 
described (Romero-López et al, 2009) and normalized with those obtained for the 
internal mRNA reference molecule encoding GAPDH (Human GAPDH Endogenous 
Control Kit, Applied Biosystems, Carlsbad, CA, USA). PCR was performed using an 
ABI PRISM 7000 Sequence Detector System and the results analysed with an ABI 
PRISM 7000 SDS software v.1.1 (both from Applied Biosystems). 
 
3. RESULTS 
 
3.1. HH363-24 effectively binds and cleaves the HCV IRES region 
HH363-24 is a hammerhead ribozyme that cleaves the HCV RNA genome at nucleotide 
363, and which has a 47 nt-long extension at its 3‟ end that acts as an aptamer for 
domain IIId of IRES. This extension contains a complementary sequence motif for the 
apical loop of domain IIId (Romero-López et al, 2005). Binding and cleavage assays 
were performed on the target molecule to further assess the catalytic and binding 
properties of the chimeric molecule. 
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The cleavage capacity of HH363-24 was tested on a molecule containing the first 691 
nucleotides of the viral RNA 5‟HCV-691 (Romero-López et al, 2005). Reactions were 
performed under single-turnover conditions to calculate the kobs value. These results 
showed HH363-24 to efficiently cleave the substrate RNA, returning a kobs of 0.042 ± 
0.006 min
-1
 (Table 1). 
The binding affinity of HH363-24 was subsequently analysed using the 5‟HCV-691gg 
construct as the target RNA (Romero-López et al, 2005). This molecule contains the 
HCV genomic sequence from nucleotides 1 to 691 plus two point mutations, U362G and 
C363G, which impede cleavage by the catalytic core. Two nanomoles of the inhibitor 
molecule were assayed against increasing amounts of the substrate RNA.  Analysis of 
the titration curve (see Table 1 and data not shown) indicated that HH363-24 bound to 
5‟HCV-691gg with high affinity, returning a Kd value of 12.28  1.31 nM.  
These results show that the engineered inhibitor HH363-24 has both catalytic and 
binding activities. 
 
3.2. The essential IIId domain of the IRES region is the target for HH363-24 
In earlier work we identified the sequence motif C54CCAACAC61 in the apical loop of 
the aptamer domain (Figure 1B; (Romero-López et al, 2005). These residues are 
complementary to the apical loop of the highly conserved IIId domain in the viral IRES 
region, i.e., G261UGUUGGG268 (Figure 1A; (Jubin et al, 2000). RNA probing assays 
were performed on both interacting molecules to confirm their interaction. 
The secondary structure of HH363-24 was first analysed to map the nucleotides 
involved in the association with the IRES region. The inhibitor was 
32P 5‟-end labelled 
and subjected to partial degradation with nucleases (RNase T1 and A) or lead (Figure 
2A). These reagents preferentially cleave single-stranded RNA, at G residues for RNase 
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T1, U or C residues for RNase A, and at any nucleotide for lead. Reactions proceeded in 
the presence of a molar excess of the non-related molecule RNA334. The data extracted 
from these assays fitted perfectly with the theoretical secondary structure predicted by 
MFold software (Zuker, 2003); Figure 1B; and data not shown), in which the catalytic 
and aptamer domains appeared as two well-defined secondary structural elements 
(Figure 1B, 2A). The aptamer region adopted a typical stem-loop secondary structure 
with an internal purine-loop and an apical loop containing the sequence motif 
C54CCAAC59 (Figure 1B, 2A). This was partially resistant to degradation by RNase A 
and lead in the presence of the 5‟UTR (5‟HCV-356; (Romero-López et al, 2005); 
Figure 2A). This confirms the involvement of the apical loop of the aptamer element in 
the interaction with the HCV IRES. 
The identification of the interacting residues in the IRES region was then analysed. For 
this purpose, the RNA construct 5‟HCV-356 was 32P 5‟-end labelled and partially 
digested with specific endonucleases and lead, as described above. Native folding of the 
IRES was confirmed with the degradation pattern, which firmly resembled that 
previously reported by other authors (Kieft et al., 1999); Figure 1A, 2B, and data not 
shown). In the presence of HH363-24, the cleavage map reproducibly showed a 
significant reduction in the accessibility of the apical loop of domain IIId (Figure 2B). 
This reflects a critical role of this element in the recruitment of HH363-24.  
 
3.3. Inhibition of the 80S ribosomal particle assembly  
Domain IIId is a functional element with essential roles in IRES-dependent translation.  
It directly recruits the ribosomal subunit 40S (Barria et al., 2009; Ji et al, 2004; 
Kolupaeva et al, 2000; Lytle et al, 2002; Otto and Puglisi, 2004) and contributes to the 
proper positioning of the IRES to constitute the productive translational complex 
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(Babaylova et al, 2009). We have previously shown moderate inhibitory activity of 
HH363-24 in in vitro translation assays (Romero-López et al, 2007). The effect of 
HH363-24 on the 80S ribosomal particle assembly was therefore investigated.  In vitro 
translation assays were performed with an internally 
32
P-labelled RNA target encoding 
the IRES region fused to the FLuc coding sequence. The 48S and 80S particles were 
resolved by sucrose density gradient ultracentrifugation and identified as two well-
defined peaks after fractioning (Figure 3). In the presence of HH363-24, the formation 
of the translational complexes 48S and 80S was clearly reduced (Figure 3), suggesting 
that the chimeric inhibitor interferes with the early steps of IRES-dependent initiation of 
protein synthesis.  
The contribution of both catalytic and aptamer activities to this effect was further 
investigated. Inactive mutants of HH363-24 for each functional domain were 
constructed and subsequently tested for their ability to interfere with the ribosomal 
complex assembly (Figure 1B). The catalytically inactive variant HH363m-24 contains 
the point mutation G15A that inhibits the cleavage activity of the hammerhead ribozyme, 
while the non-functional aptamer molecule HH363-24m has three nucleotide changes 
that abolish its aptamer binding ability (data not shown).  Finally, the completely null 
variant, HH363m-24m, combines both modifications to render a potentially inactive 
chimeric inhibitor. While the mutant in the catalytic core was still active, inactivation of 
the aptamer domain completely abolished the inhibitory effect yielding a similar 
sedimentation profile to that detected in the absence of HH363-24 (Figure 3). This 
result suggests a major contribution of the aptamer to the interference with ribosome 
recruitment shown by HH363-24. The same behaviour was observed for the fully 
inactive construct HH363m-24m (Figure 3).  
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Together, these results suggest a potential inhibitory role of HH363-24 in HCV IRES-
dependent translation via interference with the recruitment of ribosomal subunits.  This 
is likely mediated via interaction with domain IIId. 
 
3.4. Inhibition of the HCV translation and replication in cell culture by HH363-24 
The engineered molecule HH363-24 has been shown to exert a moderate inhibitory 
effect on IRES function in vitro (Romero-López et al, 2007). This might be explained 
by its interaction with IRES domain IIId, as well as the cleavage activity performed by 
the catalytic core. Thus, viral translation and replication were analysed in a human cell 
line to further investigate the antiviral role of HH363-24. 
The RNA molecule ICU (Romero-López and Berzal-Herranz, 2012), which contains the 
fluc gene flanked by both the HCV IRES and the whole 3‟ end of the viral genome 
(including the CRE region plus the 3‟UTR), was used to examine viral protein 
synthesis. It has been reported that the CRE element regulates viral translation via the 
establishment of long range RNA-RNA interactions with domains essential for IRES 
activity (Romero-López and Berzal-Herranz, 2012). This prompted attempts to use ICU 
as a surrogate of the molecular and conformational environment of the HCV genome 5‟ 
end. A human hepatic cell line, Huh-7, was co-transfected with a mixture containing the 
ICU reporter and the mRNA encoding the RLuc protein, which acted as an internal 
control. A molar excess of the chimeric inhibitor was added and the resulting luciferase 
levels compared with those obtained in the presence of a non-related RNA (RNA80). A 
significant reduction of around 80% of Fluc protein activity was detected in the 
presence of HH363-24 (Figure 4A). No significant changes were seen in RLuc protein 
synthesis (<5%; data not shown). This shows that the inhibitory activity of HH363-24 
does not affect cap-dependent translation. Tests were then performed to determine 
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whether the catalytic module and its aptamer region remained active in the engineered 
molecule ex vivo. Inactivation of either element failed to significantly influence its 
inhibitory activity (Figure 4A). No significant changes in the relative luciferase levels 
were seen for the null variant HH363m-24m with respect to the control reaction (Figure 
4A). These data show that both domains preserve their inhibitory function in cell culture 
and remain active in the chimeric compound.        
The effect of HH363-24 on HCV RNA synthesis was investigated in cell culture. Huh-7 
cells harbouring stable and autonomous subgenomic RNA replicons derived from HCV-
1b (Huh-7 NS3-3‟; (Larrea et al, 2006; Romero-López et al, 2009) were transiently 
transfected with the chimeric inhibitor or the non-related RNA80. Real time RT-PCR 
was used for relative quantification of the intracellular HCV RNA levels. The cellular 
mRNA coding for GAPDH protein was selected as an internal standard. The synthesis 
of the viral positive strand was clearly reduced to around 70% in the presence of the 
chimeric inhibitor HH363-24 (Figure 4B). Importantly, mutations in either the 
hammerhead or the aptamer regions partially impaired this activity, with inhibition 
levels close to 40% (Figure 4B). The transfection of the completely inactive variant, 
HH363m-24m, yielded no significant reduction in HCV RNA levels (Figure 4B). This 
shows that the extension of the hammerhead ribozyme with an aptamer module for 
domain IIId provides the most efficient antiviral activity.  
 
4. DISCUSSION 
 
The finding of novel therapeutic strategies for fighting multiple viral diseases is a major 
research goal.  Targeting conserved structural and functional elements of viral genomes 
with nucleic acids, particularly RNA, has been shown an effective and promising 
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alternative to non-specific antiviral treatments (Dausse et al., 2009; Puerta-Fernández et 
al., 2003; Romero-López et al, 2006). The design and engineering of therapeutic tools 
based on RNA might also provide multi-target compounds with different antiviral 
functions that could inhibit the emergence of escape variants (Jarczak et al, 2005; 
Macejak et al, 2001). We previously proposed the feasibility of this approach for the 
inactivation of essential steps of the HCV cycle, such as protein synthesis and 
replication (Romero-López et al, 2005; Romero-López et al, 2009; Romero-López et al, 
2007). This manuscript analyzes the mechanism of action of the potential HCV 
inhibitor, HH363-24. It is composed of a ribozyme core (which cleaves the viral 
genome at position 363) attached to an aptamer element for the conserved structural 
domain IIId in the IRES region. Both activities remain in vitro and ex vivo in the 
engineered molecule and their combination is a requisite for the strongest antiviral 
effect (Table 1, Figure 4), suggesting that they cooperate in the overall conformation 
and functionality of HH363-24. This shows the potential of the method used (Romero-
López et al, 2005) to select these compounds. Unfortunately, neither the present nor 
earlier data show whether the cleavage and domain IIId binding activities are 
undertaken by the same molecules. Indeed, previous data suggest that the inhibitory 
function of these chimeras cannot be explained by an additive effect of their 
independent modules (Barroso-delJesus et al, 2005; Kikuchi et al., 2009; Puerta-
Fernández et al, 2005; Romero-López et al, 2005; Romero-López et al, 2009; Romero-
López et al, 2007).  
The results show that the IIId domain in the IRES is the main anchoring site of HH363-
24 (Figure 2B). The isolation of aptamers that bind to domain IIId has previously been 
reported (Kikuchi et al., 2005). This „selection convergence‟ could be determined by the 
structural features of domain IIId, which is especially prone to interact with other viral 
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genomic elements and proteins (Babaylova et al, 2009; Kolupaeva et al, 2000; Lafuente 
et al, 2002; Romero-López and Berzal-Herranz, 2009; Shimoike et al, 1999). The three-
dimensional structure of domain IIId, resolved by NMR, reveals the formation of a stem 
with non-canonical pairings, closed by a highly disordered apical hexaloop (Klinck et 
al, 2000; Lukavsky et al, 2000). This adopts the so-called U-turn motif (Babaylova et al, 
2009; Jubin et al, 2000; Klinck et al, 2000; Kolupaeva et al, 2000; Lukavsky et al, 
2000), a widespread element employed by many RNA molecules to efficiently interact 
with other functional RNA domains or proteins (Brunel et al., 2002). Therefore, 
selection convergence may be influenced by the specific structural properties of domain 
IIId. This entails the recognition of a three-dimensional architecture by the aptamer, 
which provides increased specificity compared to antisense or siRNA molecules 
(Darfeuille et al., 2006). Moreover, HH363-24 interacts with the apical loop of domain 
IIId through a sequence motif located at an apical loop of the aptamer region. Apical 
loop-apical loop contact is a very efficient and commonly used mechanism for the 
regulation of biological processes (Brunel et al, 2002). This strategy could be 
successfully exploited to engineer effective inhibitory RNA molecules (Dausse et al, 
2009; Puerta-Fernández et al, 2005; Romero-López et al, 2009; Romero-López et al, 
2007).  
The present work shows that targeting domain IIId efficiently interferes with the 
assembly of translational particles 48S and 80S (Figure 3). We propose that HH363-24 
inhibits the formation of active ribosomal complexes by the direct apical loop-apical 
loop interaction between the aptamer region and the domain IIId, leading to the efficient 
inhibition of IRES-dependent protein synthesis (Figure 3, 4A).  Moreover, the catalytic 
activity on its own significantly affects to HCV translation and replication (Figure 4) by 
directly cleaving the viral genome. Interestingly, the presence of the aptamer element on 
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its own not only reduced IRES function but also HCV RNA levels (Figure 4). This 
could be related to the fact that domain IIId has been shown to interact with the stem-
loop 5BSL3.2 (Romero-López and Berzal-Herranz, 2009), which is an essential partner 
in viral replication (Lee et al., 2004; You et al., 2004). This contact regulates HCV 
IRES function (Romero-López and Berzal-Herranz, 2012), but no information exists 
regarding its involvement in viral replication. Thus, these data are insufficient to 
propose a detailed mechanism that could explain the inhibitory effect observed for 
HH363m-24. The present results show that targeting domain IIId is an effective way of 
interfering with both viral protein and RNA synthesis. To our knowledge, this is the 
first report describing this effect. Hence, the chimeric inhibitor HH363-24 is a potential 
tool for the investigation of additional roles of domain IIId in the HCV cycle.  
In this work we have accomplished the investigation of the mechanism of action for the 
molecule HH363-24, which is a relevant issue that must be considered in the design of 
therapeutic approaches combining different inhibitor RNA molecules. The reported data 
point to domain IIId as the key target element in the antiviral activity for HH363-24, in 
contrast to previously isolated inhibitor RNAs HH363-10 and HH363-50, which target 
the highly conserved domains IIIf  (Romero-López et al, 2007) and IV (Romero-López 
et al, 2009), respectively. Domain IIIf participates in the formation of a pseudoknot 
structure (Berry et al., 2011), an essential partner in the formation of translationally 
active complexes (Wang et al., 1995), while domain IV efficiently positions the 
translation start codon at the P site (Ji et al, 2004; Lytle et al, 2002). Thus, the effect 
these molecules, HH363-10 and HH363-50, on ribosomal complex assembly and viral 
replication considerably diverges from that observed for HH363-24, resulting in 
different inhibitory effects for both the wild-type and the different mutant constructs 
tested. This argues for the importance of understanding the pathways that lead to the 
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observed inhibitory effect. Moreover, the combination of inhibitor RNA molecules that 
interfere with different steps of essential routes for the viral cycle may provide novel 
efficient anti-HCV strategies.  
Taken together, the present results confirm the effectiveness of adding an aptamer 
module to the 3‟ end of a plain hammerhead ribozyme for the efficient targeting of 
genomic domains in viral RNAs (Barroso-delJesus et al, 2005; Puerta-Fernández et al, 
2005; Romero-López et al, 2005; Romero-López et al, 2009; Romero-López et al, 
2007). The investigations of the mechanism of action by which HH363-24 exerts its 
activity may contribute to further rationale designs of novel anti-HCV agents with 
improved inhibitory properties. The engineering of molecules with dual specificity and 
activity could help prevent the appearance of escape variants and encourage strong 
interference of viral propagation.  
 
5. CONCLUSSIONS 
 
The engineering of RNA compounds with different specificities and activities is a 
promising alternative strategy to generic antiviral treatments. They would provide 
strong inhibitory effects and could restrain the emergence of resistant virus variants. 
The selected molecule HH363-24 efficiently inhibits both HCV translation and 
replication, showing a potential antiviral activity. This calls for future investigations in 
the development of RNA conjugates with high internalization rates and intracellular 
stability. Finally, HH363-24 has great potential as a novel tool to study the functional 
contribution of domain IIId to the HCV cycle.    
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Figure legends 
 
Figure 1. The HCV-IRES domain and HH363-24. A) Representation of the secondary 
structure of the HCV IRES. Nucleotides involved in the interaction with HH363-24 are 
marked in bold. The translation start codon is shown in italics. The cleavage site for 
HH363 is indicated by an arrow. Numbering corresponds to nucleotide positions of the 
HCV Con1 isolate, genotype 1b. B) The proposed secondary structure of HH363-24 as 
determined by MFold software analysis and using experimental constraints. Helix 1 and 
Helix 3 denote the interacting residues of the catalytic domain with its target sequence 
in the RNA substrate. The aptamer domain is boxed. Residues involved in the 
association with domain IIId of the HCV IRES are indicated in bold. Encircled 
nucleotides were mutated as indicated to generate the respective inactive variants. 
 
Figure 2. Probing assays of the IRES:HH363-24 complex. A) The figure shows an 
autoradiograph of the probing assay for HH363-24 in the absence (-) or presence (+) of 
the target RNA 5‟HCV-356. Digestion reactions were initiated by the addition of 
hydrolytic reagents (RNase T1, RNase A or Pb
2+
). Specific cleavage products were 
resolved in 6% high resolution denaturing polyacrylamide gels. Residues involved in 
the interaction with the HCV-IRES are boxed. B) Identification of the targeted 
nucleotides in the substrate RNA 5’HCV-356. Trace amounts of the 32P 5’ end-labelled 
5’HCV-356 construct were partially digested with RNase T1, RNase A or Pb2+, either in 
the absence (-) or presence (+) of HH363-24. Nucleotides resistant to degradation are 
boxed. C, control reaction without hydrolytic reagents. OH, alkaline ladder. T1L, T1 
cleavage ladder.  
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Figure 3. The aptamer domain prevents the formation of the 48S and 80S translational 
particles. Sucrose gradient sedimentation profiles of 
32
P-internally labelled IRES-FLuc 
mRNA incubated in rabbit reticulocyte lysates in the absence and presence of a molar 
excess of the RNA molecules HH363-24, HH363m-24, HH363-24m or HH363m-24m. 
Filled circles, control reaction profile; open circles, sedimentation profile with the 
inhibitor. In all cases, the percentage disintegrations are represented against the 
corresponding gradient fraction number. The 48S and 80S complexes are indicated. 
Fractions were collected from the top downwards. 
 
Figure 4. HH363-24 inhibits IRES-dependent translation and HCV replication in a 
hepatoma cell line. A) Huh-7 cells were co-transfected with different amounts of 
inhibitory RNAs and 1.5 μg of a mixture containing the transcripts IRES-FLuc and 
RLuc. IRES function was measured as the activity of FLuc protein and normalized to 
that obtained for RLuc. Luciferase activity in the control reactions was established as 
100%. Data points are the mean of at least three independent experiments. B) Inhibitory 
RNAs were transfected into Huh-7 cells stably supporting viral replication, Huh-7 NS3-
3‟. Intracellular total RNA was isolated 18 h after transfection and used for real time 
RT-PCR to measure viral RNA levels, which were referred to those detected for 
GAPDH mRNA. The results were analysed using ABI PRISM SDS Software 1.1 
(Applied Biosystems). 
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Table 1. Binding and cleavage constants of the inhibitor RNA HH363-24 
 
Binding  Cleavage 
Kd (nM) Bmax (%)  kobs (min
-1
) a (%) 
12.28  1.31 91.88  2.34  0.042 ± 0.006 71.43 ± 3.81 
 
Values are the means of four independent trials  the standard deviation. Kd, 
dissociation constant; Bmax, final amplitude of the binding formation; kobs, rate constant 
of the cleavage reaction; a, cleavage reaction amplitude.  
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